Skip to main content

Table 1 Reduction in active NSPs in sputum and in WBCs at Week 4 relative to placebo

From: Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial

NSP

Brensocatib

Week

WBCsa

Sputumb

NE

10 mg

4

− 20%

− 86%

 

25 mg

4

− 62%

− 91%

PR3

10 mg

4

NA

− 21%

 

25 mg

4

NA

− 53%

CatG

10 mg

4

NA

− 90%

25 mg

4

NA

− 93%

  1. The mean NSP activity at week 4 for the 10 and 25 mg brensocatib groups was compared to that for the placebo group at week 4 to determine a percent reduction relative to placebo. NA not applicable
  2. aReduction in arithmetic mean
  3. bReduction in geometric mean
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us